:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2020/e/b/AD3XYNQjmBi7l9haThHg/captura-de-tela-2020-11-12-154237.jpg)
[ad_1]
The president of Pfizer No Brazil, Carlos Murillo, said Thursday that, globally, the company will have manufactured 50 million vaccines against covid-19 until the end of 2020. Murillo acknowledged that the number is low in view of world demand, but said that the plan is to reach 1.3 billion doses in a few months, already in early 2021. The president of Pfizer in Brazil participated in a symposium on vaccines against coronavirus organized by the National Academy of Medicine.
Murillo gave details about the manufacturing process and price of the product. For the first time, he said, production is not sequential. In practice, the effectiveness tests are being carried out in parallel with the manufacture of the vaccine, which will be distributed according to the statement from the regulatory agencies of the countries.
- Pfizer plans to vaccinate against covid-19 in Brazil in the first quarter of 2021
At first, he explained, this production will be concentrated in three factories in the United States and two in Germany, and only in a second moment may there be a transfer of technology for production in other countries, such as Brazil, where they would have already discussed with the Oswaldo Cruz Foundation (Fiocruz).
Murillo explained that concentrated production is ideal for the emergency context, because the chosen manufacturing plants are the most modern and prepared by the company.
On prices, Murillo did not reveal the figures, but said that Pfizer made the decision to create three different tracks, the application of which will depend on the development of each country. There will therefore be a higher price for the more advanced countries, such as the United States and Europeans, a price for the intermediate countries, where Brazil fits, and a third lower price for the less developed countries, “like Bolivia”. where Murillo is from.
Murillo said that Pfizer has already invested more than $ 2 billion in its synthetic vaccine against COVID-19. Unlike traditional vaccines, which begin with the injection of the weakened pathogen into the human body, the Pfizer vaccine is based on messenger RNA technology, through which strands of genetic instructions called messenger RNA are injected into the body. inducing the manufacture of related proteins. to the virus that, by itself, is harmless, but generates an immune response in the body.
According to preliminary tests, the effectiveness of the vaccine is greater than 90% and it is necessary to wait 28 days for the vaccine to take effect.
